Stockscreener 앱 받기
86.64
1.23%
1.05
Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스
Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data - Stocktwits
Avoro Capital discloses 9.64% Arrowhead Pharmaceuticals (ARWR) stake including warrants - Stock Titan
Why Arrowhead Pharmaceuticals (ARWR) Is Back In The Spotlight - sahmcapital.com
Assenagon Asset Management S.A. Grows Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses - simplywall.st
FY2026 Earnings Estimate for ARWR Issued By HC Wainwright - MarketBeat
Zacks Research Analysts Increase Earnings Estimates for ARWR - MarketBeat
Pacer Advisors Inc. Invests $1.50 Million in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, HC Wainwright Analyst Says - marketbeat.com
Morgan Stanley Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $120 - Moomoo
Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $110.2, Implies 23% Upside - TradingView
Arrowhead buys PRV for $215M; Twist hopes to raise $300M in public offering - Endpoints News
Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ... - Yahoo Finance
Arrowhead Pharmaceuticals Q3 Earnings Call Highlights - marketbeat.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Announces Quarterly Earnings Results - MarketBeat
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Arrowhead Pharmaceuticals Inc.R (HDP1.DU) Q3 FY2026 earnings call transcript - Yahoo Finance
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher - Arrowhead Pharmaceuticals, Inc.
The Manufacturers Life Insurance Company Has $10.06 Million Stake in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
California State Teachers Retirement System Has $9.05 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)August 3, 2026 - BioSpace
Janus Henderson Group PLC Acquires 156,544 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Vanguard unit discloses 6.38M Arrowhead (ARWR) shares, a 4.53% stake - Stock Titan
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Dual Phase 3 RNAi Cardiometabolic Milestones - Yahoo Finance
Arrowhead Pharmaceuticals, Inc. $ARWR Position Cut by Arrowstreet Capital Limited Partnership - MarketBeat
Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $105.4, Implies 23% Upside - TradingView
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - BioSpace
Arrowhead Pharmaceuticals Advances Zodasiran Study for HoFH Trea - GuruFocus
Arrowhead Pharmaceuticals Inc - TradingKey
BlackRock discloses 10.1% Arrowhead Pharmaceuticals (ARWR) stake in latest 13G/A - Stock Titan
ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval - Stocktwits
Arrowhead Pharmaceuticals (ARWR) Completes Enrollment in YOSEMITE Trial - GuruFocus
H.C. Wainwright raises Arrowhead Pharma price target to $115 on trial data - Investing.com Canada
Arrowhead's Rare Cholesterol Disease Study Reaches 70 Patients - Stock Titan
Arrowhead Pharmaceuticals Inc (ARWR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arrowhead Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – BX:HDP1 - TradingView
Allspring Global Investments Holdings LLC Purchases 47,902 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – XETR:HDP1 - TradingView
Is Arrowhead Pharmaceuticals on the Cusp of a Major Breakout - Kavout | AI
Bank of New York Mellon Corp Acquires 72,296 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo! Finance Canada
The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High - Investor's Business Daily
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company? - Trefis
ARWR Reiterated by Piper Sandler -- Price Target Raised to $126 - GuruFocus
H.C. Wainwright reiterates Arrowhead Pharma stock rating on trial data By Investing.com - Investing.com Canada
Arrowhead shares surge as Phase III plozasiran studies deliver positive pancreatitis data - The Pharma Letter
Hsbc Holdings PLC Buys Shares of 151,046 Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Hits 52-Week High Following Pos - GuruFocus
Arrowhead Pharmaceuticals (ARWR) Reports Positive Phase 3 Trial Results - GuruFocus
Arrowhead (ARWR) Sees Significant Stock Surge - GuruFocus
Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $101.6, Implies 36% Upside - TradingView
ARWR Stock Climbs As EU Greenlights REDEMPLO And Analysts Boost Targets - timothysykes.com
Arrowhead rises on phase III hypertriglyceridemia readout - BioWorld News
ARWR Maintained by Chardan Capital -- Price Target Raised to $115 - GuruFocus
Arrowhead Pharmaceuticals Shares Rise After Phase 3 Trials of Plozasiran Meets Primary, Secondary Endpoints - Moomoo
0.52%
0.07%
자본화:
|
볼륨(24시간):